Sun Pharmaceuticals is trading higher by 3% at Rs 564 in otherwise weak market in morning trades after the company on Wednesday after market hours said that it has received approval from the US health regulator for its generic Zyprexa Zydis tablets, used in treating mental disorder, in the American market.
“The US Food and Drug Administration (USFDA) have granted an approval for its abbreviated new drug application (ANDA) for generic version of Zyprexa Zydis, Olanzapine ODT, in strengths of 5 mg, 10 mg, 15 mg and 20 mg,” Sun Pharma said in a filing to the stock exchanges.
"These generic Olanzapine orally disintegrating tablets, 5 mg, 10 mg, 15 mg and 20 mg are therapeutic equivalents of Eli Lilly's Zyprexa Zydis tablets," it added.
A combined around 20,000 shares have changed hands on the counter so far on the NSE and BSE.